Biotech | November 25, 2021
GreenLight Biosciences and Samsung Biologics to build vaccine capacity
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Launching in 2022, its availability will be expanded to the global market
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
The new facility will provide an important boost to vaccine capacity in Africa
Subscribe To Our Newsletter & Stay Updated
